A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
NCT06971614
Recruiting
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: East Valley Urology Center, Queen Creek, Arizona +1 locations
Conditions: Nonmuscle-invasive Bladder Cancer
Register for Updates
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
NCT06503731
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation. After a screening period of up to 6 weeks, eligible participants will be randomized in a 1:1:1 ratio. The study drug will be administered subcutaneously while patients remain on their standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, steroids) during... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +16 locations
Conditions: Antibody-mediated Rejection
Register for Updates
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840
Recruiting
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +26 locations
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona +88 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
NCT06500884
Recruiting
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of California San Francisco, San Francisco, California +26 locations
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/17/2025
Locations: Alabama Kidney Research, Alabaster, Alabama +838 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786
Recruiting
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +9 locations
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895
Recruiting
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Iowa Hospital and Clinics, Iowa City, Iowa +11 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
NCT05683418
Recruiting
The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the maximum tolerated dose and recommended dose for phase 2? 2. how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California +17 locations
Conditions: Squamous Cell Carcinoma of Head and Neck, Endometrial Cancer, HR+/HER2-negative Breast Cancer, Bladder Cancer
Register for Updates
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515
Recruiting
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Alaska Oncology and Hematology LLC, Anchorage, Alaska +208 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
NCT05929976
Recruiting
Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-... Read More
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/17/2025
Locations: Columbia University Irving Medical Center, New York, New York +7 locations
Conditions: Acute Lymphoblastic Leukemia, Nutrition Aspect of Cancer, Microtia, Genetic Predisposition
Register for Updates
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
NCT06025292
Recruiting
We will be directly comparing a high-quality protein diet composed primarily of lean pork loin (PORK) to a lower-quality plant-based protein diet (PLANT) in individuals with prediabetes on muscle and whole-body protein turnover and glucose regulation.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
07/17/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Hyperglycaemia (Non Diabetic), Prediabetes
Register for Updates